Fat premium
25 November 2019

The Swiss drugs giant is buying The Medicines Co. and its artery-clearing drug inclisiran for $9.7 bln, or a fat 41% premium. But the sector is crowded and Novartis must wait years for a decent return. Governments and insurers may also tire of paying to treat lifestyle diseases.